anti-c-myb hammerhead ribozymes (Ribozyme)

N/A

Report date: 2025/02/01 20:00:06

NME

Base Information

Drug Nameanti-c-myb hammerhead ribozymes (Ribozyme)

Drug Alias Nameribozymes c-myb (Ribozyme)

ClassificationSmall molecules > Nucleosides and nucleotide derivtives > OligonucleotideSmall molecules > Nucleosides and nucleotide derivtives > Ribozyme

Mechanisms of Actionc-myb expression inhibitors

TargetsTranscriptional activator Myb

Therapy Area/IndicationsCoronary Restenosis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesSirna Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesSirna Therapeutics Inc Chiron Corp

Active IndicationsN/A

Inactive IndicationsCoronary Restenosis

Other Information

ATC CodeN/A